1 Results from in vitro experiments on the phrenic nerve-diaphragm and the hypogastric nerve-vas deferens preparations of the guinea-pig have been used to plot log concentration-effect curves for skeletal neuromuscular and ganglion blockade, respectively, for (+)tubocurarine, pancuronium, alcuronium, gallamine and fazadinium (AH 8165).
Introduction
The non-depolarizing skeletal muscle relaxants produce other effects in addition to blockade of neuromuscular transmission (Paton, 1959) . In clinical use, the most significant of these effects is manifested usually as a change in heart rate and blood pressure. An ability to block autonomic ganglia is one of the properties shared by the non-depolarizing compounds used as muscle relaxants. The potency of the compounds in blocking ganglia has been measured usually on anaesthetized cats (Marshall, 1973; Hughes & Chapple, 1976) . It would be useful to be able to establish relative neuromuscular and ganglion blocking potencies on simple isolated tissue preparations in which effective concentrations would be known and the wide range of concentration from the absence of neuromuscular blockade to complete ganglion blockade could be covered easily. Ideally, this should be done on a skeletal muscle and a ganglion preparation from the same species.
We now describe measurements made in vitro, on tissues from a single species, of the neuromuscular and sympathetic ganglion blocking potencies of most of the non-depolarizing muscle relaxants in current clinical use. The phrenic nerve-diaphragm and the 0007-1188/80/110501-06 $01.00 hypogastric nerve-vas deferens preparations of the guinea-pig have been used. Potencies and potency ratios obtained from this species were compared with those available from measurements obtained by other methods on other species.
Methods
The guinea-pig isolated phrenic nerve-diaphragm preparation One phrenic nerve-hemidiaphragm preparation was removed from male guinea-pigs (600 to 950 g) as described, for the rat, by Bulbring (1946) with the pre-drug control response. The means of these changes were plotted as log concentration-effect curves ( Figure 1 , dotted lines for diaphragm, solid lines for vas deferens). Regression lines for the concentrations of each drug which produced effects over the linear part of the log concentration-effect curve were used to calculate that concentration (with 95% confidence limits) which would produce a 50% blockade (EC50). These EC50s are shown in Table 1 together with, for the muscle relaxants, the ratio between the EC50 for ganglion blockade and the EC50 for neuromuscular blockade (the equipotent molar ratio, epmr). The muscle relaxants, (+ -tubocurarine, alcuronium and fazadinium produced neuromuscular blockade at concentrations lower than those needed for ganglion blockade, but all were capable of producing complete blockade of ganglionic transmission. For this group of drugs, the difference between the neuromuscular blocking and ganglion blocking potencies was largest for alcuronium (epmr 22.9) and smallest for fazadinium (epmr 2.3).
A wider separation of neuromuscular and ganglion blocking potency was found for pancuronium (epmr 200.0). For pancuronium and gallamine the onset of ganglion blockade was delayed by the appearance, at lower concentrations, of an augmentation of the response of the vas deferens to hypogastric nerve stimulation (a maximum augmentation of the order of 12% for gallamine and 18% for pancuronium.)
The three ganglion blocking agents were each capable of producing full blockade of ganglionic transmission with the order of potency being pentolinium > trimetaphan > hexamethonium.
Discussion
The results obtained in the present investigation allow a comparison to be made within one mammalian species of the relative potencies for neuromuscular blockade and sympathetic ganglion blockade of most of the non-depolarizing muscle relaxants in current clinical use. The in vitro assay of ganglion blocking potency depended on the presence of a ganglionic relay in the hypogastric nerve innervating the vas deferens of the guinea-pig (Sjostrand, 1962; Bentley & Sabine, 1963; Birmingham & Wilson, 1963) . By separate stimulation of the preganglionic fibres of the hypogastric nerve and of the postganglionic nerve terminals within the wall of the vas deferens (Birmingham & Wilson, 1963) it is possible to localize the blocking effect of a drug to sympathetic ganglia. The experimental technique was validated by the measurement, in vitro, of the potency of three classic ganglion' blocking agents, hexamethonium, trimetaphan and pentolinium; each was capable of producing complete blockade of the response to hypogastric nerve stimulation at a time when the response to transmural stimulation of intramural nerves was not reduced. In the same way, each Taylor, Prior & Bevan (1964) measured the potency of (+ )tubocurarine and gallamine on guinea-pig isolated diaphragm stimulated with single shocks through the phrenic nerve. After full paralysis, they successively reduced the bath concentration of drug to measure the degree of blockade at equilibrium (15 to 20min). They obtained an EC50 for (+)-tubocurarine of 1.5 pg/ml (1.9 x 10-6 M) comparable with our mean value of 6.7 x 10-6 M. Their ratio EC50 (+ -tubocurarine/EC50 gallamine was 0.18 which is close to our value of 0.22.
On the other hand Lu (1970) , also using the guineapig diaphragm, obtained EC50s of 0.35 x 10-6 M and 3.09 x 10-6 M for (+ -tubocurarine and gallamine respectively. These are smaller than our values and those of Taylor et al. (1964) and the ratio was 0.11. Chou (1947) reported an EC50 for (+)-tubocurarine based on 3 min equilibration on the rat isolated diaphragm of 1.8 pg/ml (2.3 x 10-6 M); we obtained 6.7 x 10-6 M on the guinea-pig. Chou (1947) Brittain & Tyers (1973) found ECsos of 0.68 pg/ml (1.58 x 10-6M) for fazadinium and 0.09tg/ml (0.15 x 10-6M) for pancuronium; these may be compared to our values of 28.0 x 10-6M and 1.1 X 10-6 M respectively. For gallamine our EC50 of 30.0 x 1O-6 M is closer to that of Brittain & Tyers (1973) who reported 16.5 jig/ml (23.3 x 10-6 M).
Potency measurements have been made also on intact animals and on man. Where it is possible to use published data to calculate potency ratios between drugs these may be compared with ratios calculated from our results. Brittain & Tyers (1973) obtained intravenous paralysing doses for mice and the ratio ED50 fazadinium/ED50 pancuronium was 13.6; our ratio EC50 fazadinium/EC50 pancuronium was 25.5. Gallamine is again different being 27.3 times less potent than pancuronium in our measurements but 119.4 times less potent when tested on mice by Brittain & Tyers (1973) . Some comparisons are possible with measurements made on man. For fazadinium the ED50 of 0.098 mg/kg obtained by Brittain & Tyers (1973) for paralysis of mice was close to the ED50 of 0.11 mg/kg found by Hussain, Healy & Birmingham (1979) for reduction of thumb twitch in anaesthetized patients. Lund & Stovner (1970) published intravenous ED50s for reduction of grip strength in conscious subjects for pancuronium, alcuronium and (+ )tubocurarine. When calculated with respect to pancuronium the potency ratios were 0.33 for alcuronium and 0.26 for (+ )tubocurarine; comparable figures from our in vitro EC50s were 0.79 and 0.16 respectively. It would seem therefore that comparisons between species and between methods of measurement should be approached with caution.
The propensity of skeletal muscle relaxants to produce some degree of autonomic ganglion blockade is well known. Paton (1959) referring to the ganglionblocking activity of (+ )-tubocurarine wrote "Its potency is not far short of that of hexamethonium".
Our measurements confirm this. The EC50 of (+ )-tubocurarine for blockade of the hypogastric ganglia was 4.5 x 10' M whereas that for hexamethonium was 2.5 x I0-5 M. In clinical use an important factor will be the separation between the dose producing adequate muscle relaxation and that producing significant ganglion blockade. This separation may be expressed as the ratio between the doses producing the same degree of neuromuscular blockade and ganglion blockade. These equipotent ratios are shown in Table 1 for our in vitro measurements of sympathetic ganglion blockade. They range from 2.3 for fazadinium to 200.0 for pancuronium. The curves in Figure 1 show the five muscle relaxants to fall into two groups: Group 1, comprising (+ )tubocurarine, alcuronium and fazadinium, in which, as the concentration is increased, ganglion blockade follows neuromuscular blockade without an intervening augmentation of response to preganglionic stimulation; Group 2, comprising pancuronium and gallamine, in which the onset of ganglion blockade is preceded by an augmenting effect at lower concentrations.
Our ganglion-blocking/neuromuscular blocking potency ratio of 2.3 for fazadium may be compared with that of 3.8 based on ED30 measurements of blockade of contractions of tibialis anterior and of nictitating membrane in the anaesthetized cat made by Marshall (1973 In clinical use as skeletal muscle relaxants both pancuronium (Loh, 1970;  Komesaroff, 1970; Kelman & Kennedy, 1970; 1971) and gallamine (Marbury, Artusio, Wescoe & Riker, 1951; Smith & Whitcher, 1967; Kennedy & Farman, 1968) increase blood pressure and heart rate. These effects have been the subject of much investigation. For either drug the tachycardia has been ascribed to a selective blockade of cardiac vagal muscarinic receptors (Saxena & Bonta, 1970; Clark & Mitchelson, 1976) . In addition, an indirect sympathomimetic action of gallamine has been reported by Brown & Crout (1970) and a sympathomimetic effect of pancuronium has been shown by Ivankovich, Miletich, Albrecht & Zahed (1975) to be associated with a blockade of noradrenaline neuronal uptake. These sympathomimetic mechanisms may explain the initial augmentation by pancuronium and gallamine of the response of the guinea-pig vas to hypogastric nerve stimulation. It cannot be ascribed solely to an action at the ganglion because other work in this laboratory has shown the potentiation to apply also to post-ganglionic stimulation and to exogenously applied noradrenaline (Kapur & Tomlinson, personal communication).
We recognise that results obtained on isolated preparations of the diaphragm and a sympathetic ganglion are not necessarily predictive for man or animals of the relative effects on skeletal muscle and on heart rate and blood pressure. At muscle relaxing doses the effect on the cardiovascular system will be related to the resultant of the relative effects of blockade at sympathetic ganglia and parasympathetic (cardiac vagal) sites.
